Twilight Litaka Pharma has reported results for first quarter ended June 30, 2012.
On standalone basis, the company has reported a fall of 83.38% in its net profit at Rs 2.13 crore for the quarter, as compared to Rs 12.82 crore for the same quarter in the previous year. Total income of the company has decreased by 12.65% to Rs 160.33 crore for the quarter under review as compared to Rs 183.55 crore for the quarter ended June 30, 2011.
Twilight Litaka Pharma has well equipped, modern manufacturing testing and packaging facilities at all its plants viz. Pimpri, Vadgaon and Vasai. The Pimpri Plant has been approved by Dept. of Science and Technology, Government of India for its R & D facilities. The plants at Vadgaon and Pimpri have also been approved by the Pune University for laboratory use by its students pursuing the Doctorate Degrees.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: